These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24128106)

  • 1. [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
    Guglieri-López B; Ventura-Cerdá JM; Carmena-Carmena J; Climente-Mónica M
    Farm Hosp; 2013; 37(5):419-21. PubMed ID: 24128106
    [No Abstract]   [Full Text] [Related]  

  • 2. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
    McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
    N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
    Taylor N; Melchardt T; Grundbichler M; Strasser M; Egle A; Greil R
    Ann Hematol; 2013 Jul; 92(7):1001-2. PubMed ID: 23269533
    [No Abstract]   [Full Text] [Related]  

  • 5. Eltrombopag in thrombocytopenia.
    Lawson A
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
    [No Abstract]   [Full Text] [Related]  

  • 6. Eltrombopag in chronic hepatitis C.
    Mihăilă RG; Cipăian RC
    World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
    Tillmann HL; Patel K; McHutchison JG
    Curr Gastroenterol Rep; 2009 Feb; 11(1):5-14. PubMed ID: 19166653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
    Modi Y; Shaaban H; Gauchan D; Maroules M
    J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag (Revolade ) and thrombocytopenia in patients with hepatitis C. Hepatotoxic drug; more harms than benefits.
    Prescrire Int; 2015 Sep; 24(163):208-9. PubMed ID: 26417629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract]   [Full Text] [Related]  

  • 11. Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
    Zhang J; Thapar M; Farrell C; Wire MB
    Pharm Res; 2015 Jun; 32(6):2015-28. PubMed ID: 25534682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
    Scheinberg P; Singulane CC; Barbosa LS; Scheinberg M
    Clin Rheumatol; 2014 Sep; 33(9):1347-9. PubMed ID: 24740463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Eliminating the gray zone. What can be done in normal ALT values?].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():75. PubMed ID: 15373059
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
    Gauchan D; Shaaban H; Gedeon D; Maroules M
    Ann Hematol; 2014 Oct; 93(10):1777-8. PubMed ID: 24554304
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
    Maan R; de Knegt RJ; Veldt BJ
    Drugs; 2015 Nov; 75(17):1981-92. PubMed ID: 26501978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
    Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
    Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
    [No Abstract]   [Full Text] [Related]  

  • 17. Difficult management of triple therapy for chronic hepatitis C in a patient on haemodialysis.
    Plana L; Peño L; Urquijo JJ; Diago M
    Gastroenterol Hepatol; 2017 May; 40(5):356-358. PubMed ID: 27048917
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic assessment of eltrombopag in the treatment of thrombocytopenia.
    Romano F; Ruggeri M; Coretti S; Giannini EG; Sacchini D; Annichiarico BE; Marchetti M; Rodeghiero F; Lidonnici D
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):713-20. PubMed ID: 26176754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
    Trautmann K; Jakob C; von Grünhagen U; Schleyer E; Brümmendorf TH; Siegert G; Ehninger G; Platzbecker U
    Thromb Haemost; 2012 Aug; 108(2):397-8. PubMed ID: 22739569
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
    Bräu N
    J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.